# Novo Nordisk invests $2.3 billion in France for obesity drug production

Novo Nordisk announced a $2.3 billion investment to boost production capacity for obesity and diabetes drugs at its site in Chartres, France, including Ozempic and Wegovy.

- Type: Investment
- Announced: 2023-11-23
- Where: Chartres, France
- Value: $2.30B
- Status: announced
- Products: Ozempic, Wegovy, obesity drugs
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novo Nordisk](https://endata.com/companies/17868.md)

## Sources

- [uk.investing.com](https://uk.investing.com/news/stock-market-news/novo-nordisk-invests-23-million-in-france-to-boost-output-3247314), 2023-11-23: "Novo Nordisk on Thursday announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France as it races to meet soaring demand."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.